Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

7-month, prospective, randomized, placebo-controlled double-blind trial of omalizumab in children with allergic asthma who require daily corticosteroid treatment

Next Previous
Search
Trial Profile

7-month, prospective, randomized, placebo-controlled double-blind trial of omalizumab in children with allergic asthma who require daily corticosteroid treatment

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jul 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use

    • Most Recent Events

    • 07 Jul 2016 Results published in a Genentech media release.
    • 07 Jul 2016 According to a Genentech media release, t0he US FDA has approved omalizumab (Xolair) for the treatment of moderate to severe persistent asthma in children six to 11 years of age. The approval was supported from by data from this and other phase III trials.
    • 01 Mar 2016 According to a Genentech media releae, the US FDA has accepted for review the company's supplemental Biologics License Application (sBLA) to extend the indication of Xolair (omalizumab) in allergic asthma to pediatric patients. The sBLA was supported by this and other phase III trials.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top